Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination

Cancer cell lines are essential tools used in many areas of biomedical research. Using the last release of the UMD_p53 database (2007) , we analysed the p53 status of 1,211 cell lines published between 1989 and 2007. p53 mutations in cell lines from various types of cancers display a striking similarity in the distribution of mutations and in the pattern of mutational events compared to tumours, indicating that they are representative of the cells from which they were derived. Analysis of the residual transcriptional activity of p53 mutants identified in cell lines that displayed two different p53 mutations show that there is a high frequency of weak mutations that are paired with more potent mutations suggesting a driver / passenger configuration. Strikingly, we found discrepancies in the p53 status for 23% (88/384) of cell lines, for which the p53 status was established independently in two laboratories. Using the NCI-60 cell line panel as a model widely used in the literature, the p53 status could not be ascertained for 13 cell lines due to a lack of homogeneous data in the literature. Our study clearly confirms that misidentified cell lines are still a silent and neglected danger and that extreme care should be taken as a wrong p53 status could lead to disastrous experimental interpretations. The p53 web site has been updated with new sections describing the p53 status in the majority of cell lines and a special section devoted to cell lines with controversial p53 status.

[1]  R. Chatterjee.  When 60 Lines Don't Add Up , 2007, Science.

[2]  Dana Ravid,et al.  A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. , 2007, Cancer letters.

[3]  Richard Lugg,et al.  Mutation analysis of 24 known cancer genes in the NCI-60 cell line set , 2006, Molecular Cancer Therapeutics.

[4]  Ying Liu,et al.  Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S. Kato,et al.  Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection , 2006, Clinical Cancer Research.

[6]  D. Grochová,et al.  Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124. , 2005, Oncology reports.

[7]  Y. Shimada.  Researchers Should Have Respect for the Originator of the Cell Lines , 2005, Clinical Cancer Research.

[8]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[9]  K. Tsuneyama,et al.  Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines. , 2005, Pathology, research and practice.

[10]  S. Kato,et al.  Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations , 2005, Human mutation.

[11]  A. Krainer,et al.  Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1 , 2004, Human mutation.

[12]  K. Schulmann,et al.  Familial adenomatous polyposis: Aberrant splicing due to missense or silent mutations in the APC gene , 2004, Human mutation.

[13]  Gertrude Case Buehring,et al.  Cell line cross-contamination: How aware are mammalian cell culturists of the problem and how to monitor it? , 2004, In Vitro Cellular & Developmental Biology - Animal.

[14]  Ourania Horaitis,et al.  The challenge of documenting mutation across the genome: The human genome variation society approach , 2004, Human mutation.

[15]  S. Kato,et al.  Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library* , 2004, Journal of Biological Chemistry.

[16]  W. El-Deiry.  The role of p53 in chemosensitivity and radiosensitivity , 2003, Oncogene.

[17]  S. Kato,et al.  Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. Pützer,et al.  p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. , 2003, Cancer research.

[19]  P. Chumakov,et al.  Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. , 2003, Cancer Research.

[20]  D. Tong,et al.  Comparison of p53 Mutational Status with mRNA and Protein Expression in a Panel of 24 Human Breast Carcinoma Cell Lines , 2003, Breast Cancer Research and Treatment.

[21]  M. Oren,et al.  Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.

[22]  Toshihide Tsuda,et al.  The TP53 gene, tobacco exposure, and lung cancer , 2003, Human mutation.

[23]  T. Soussi,et al.  Splice mutations in the p53 gene: case report and review of the literature , 2003, Human mutation.

[24]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[25]  A. Duval,et al.  Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines , 2001, Oncogene.

[26]  S. O’Brien.  Cell culture forensics , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Antonarakis,et al.  Nomenclature for the description of human sequence variations , 2001, Human Genetics.

[28]  J. Varley,et al.  Characterization of germline TP53 splicing mutations and their genetic and functional analysis , 2001, Oncogene.

[29]  P. Rudland,et al.  Combined RAF1 protein expression and p53 mutational status provides a strong predictor of cellular radiosensitivity , 2000, British Journal of Cancer.

[30]  K. Anderson,et al.  CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. , 2000, Blood.

[31]  H. Drexler,et al.  Widespread intraspecies cross‐contamination of human tumor cell lines arising at source , 1999, International journal of cancer.

[32]  X. F. Wang,et al.  UV radiation is a transcriptional inducer of p21(Cip1/Waf1) cyclin-kinase inhibitor in a p53-independent manner. , 1999, Experimental cell research.

[33]  M. Donzelli,et al.  Apoptosis-prone phenotype of human colon carcinoma cells with a high level amplification of the c-myc gene , 1999, Oncogene.

[34]  M. Takahashi.  [Analyses of p53 mutations in breast cancers with a combined use of yeast functional assay and immunohistochemical staining]. , 1998, [Hokkaido igaku zasshi] The Hokkaido journal of medical science.

[35]  J N Weinstein,et al.  Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. , 1998, Molecular pharmacology.

[36]  X. Wang,et al.  p53 tumor‐suppressor gene: Clues to molecular carcinogenesis , 1997, Journal of cellular physiology.

[37]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[38]  C. Ishioka,et al.  Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory. , 1997, Acta medica Okayama.

[39]  R. Kanamaru,et al.  Screening the p53 status of human cell lines using a yeast functional assay , 1997, Molecular carcinogenesis.

[40]  B. Ogretmen,et al.  Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells , 1997, Oncogene.

[41]  M. Tang,et al.  Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.

[42]  W. Yung,et al.  Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. , 1996, Cancer research.

[43]  J C Reed,et al.  Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. , 1996, Cancer research.

[44]  C. Streffer,et al.  Radiation induced G1-block and p53 status in six human cell lines. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[45]  K. Rieger,et al.  Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. , 1995, British Journal of Cancer.

[46]  M. Loda,et al.  Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. , 1995, Oncogene.

[47]  M. Prados,et al.  Constitutional p53 mutations associated with brain tumors in young adults. , 1995, Cancer genetics and cytogenetics.

[48]  M. Williamson,et al.  The spectrum of TP53 mutations in bladder carcinoma , 1994, Genes, chromosomes & cancer.

[49]  R. Schäfer,et al.  Functional interaction of wild-type and mutant p53 transfected into human tumor cell lines carrying activated ras genes. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[50]  D. Brachman,et al.  p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. , 1993, Cancer research.

[51]  D. Huhn,et al.  Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. , 1993, Leukemia.

[52]  H. Westphal,et al.  Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. , 1992, Cancer research.

[53]  J. Minna,et al.  High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. , 1992, Oncogene.

[54]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[55]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[56]  W. Isaacs,et al.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. , 1991, Cancer research.

[57]  R. Metcalf,et al.  p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. , 1991, Cancer research.

[58]  B. Vogelstein,et al.  Direct sequencing from touch preparations of human carcinomas: analysis of p53 mutations in breast carcinomas. , 1991, Journal of the National Cancer Institute.

[59]  G. Gaidano,et al.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[60]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[61]  W. Bodmer,et al.  p53 mutations in colorectal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[62]  M. Haas,et al.  Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines , 1990, Molecular and cellular biology.

[63]  M. Stratton,et al.  Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. , 1990, Oncogene.

[64]  J. Bartek,et al.  Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. , 1990, Oncogene.

[65]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[66]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[67]  T. Soussi,et al.  Epithelial HBL-100 cell line derived from milk of an apparently healthy woman harbours SV40 genetic information. , 1985, Experimental cell research.

[68]  V. Rotter,et al.  Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[69]  W. Nelson-Rees,et al.  Cross-contamination of cells in culture. , 1981, Science.

[70]  J. A. Hartigan,et al.  A k-means clustering algorithm , 1979 .

[71]  C. Ishioka,et al.  Locus-specific mutation databases: pitfalls and good practice based on the p53 experience , 2006, Nature Reviews Cancer.

[72]  Y. Mizushima,et al.  Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method , 2005, Journal of Cancer Research and Clinical Oncology.

[73]  W. Schulz,et al.  Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines , 2004, Urological Research.

[74]  O. Markovic,et al.  Cell cross-contamination in cell cultures: The silent and neglected danger , 1998, In Vitro Cellular & Developmental Biology - Animal.

[75]  M. Pierotti,et al.  Detection of p53 point mutations by double‐gradient, denaturing gradient gel electrophoresis , 1997, Electrophoresis.

[76]  S. Parodi,et al.  DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. , 1997, British Journal of Cancer.

[77]  S. Schwartz,et al.  p53 mutations in bladder carcinoma cell lines. , 1994, Oncology research.

[78]  S. Steinberg,et al.  p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. , 1992, Oncogene.

[79]  A. Klein-Szanto,et al.  Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. , 1992, Oncogene.

[80]  R. Amann,et al.  Predictive Identification of Exonic Splicing Enhancers in Human Genes , 2022 .